SEC Form 4 · accession 0000880771-16-000173
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wilson Wai-Shun Cheung
Officer — CFO & Senior VP, Finance
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 2:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2016 | M | 25,000 | $0.00 | A | 25,000 | D | |
| Common Stock | Aug 12, 2016 | M | 12,500 | $0.00 | A | 37,500 | D | |
| Common Stock | Aug 12, 2016 | M | 3,000 | $0.00 | A | 40,500 | D | |
| Common Stock | Aug 12, 2016 | F | 9,396 | $10.41 | D | 31,104 | D | |
| Common Stock | Aug 12, 2016 | F | 1,128 | $10.41 | D | 29,976 | D | |
| Common Stock | Aug 12, 2016 | F | 4,698 | $10.41 | D | 25,278 | D | |
| Common Stock | Aug 16, 2016 | S | 7,802 | $10.6174 | D | 17,476 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3,F4 | — | Aug 12, 2016 | A | 30,000 | A | — | — | Common Stock | 30,000 | 229,000 | D |
| Restricted Stock UnitF5,F3,F6 | — | Aug 12, 2016 | M | 25,000 | D | — | — | Common Stock | 25,000 | 204,000 | D |
| Restricted Stock UnitF5,F3,F7 | — | Aug 12, 2016 | M | 12,500 | D | — | — | Common Stock | 12,500 | 191,500 | D |
| Restricted Stock UnitF5,F3,F8 | — | Aug 12, 2016 | M | 3,000 | D | — | — | Common Stock | 3,000 | 188,500 | D |
Explanation of responses
- F1Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
- F2Granted under the Issuer's 2015 Equity Incentive Plan.
- F3Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F4Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
- F5Granted under the Issuer's 2005 Equity Incentive Plan.
- F6Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
- F7Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
- F8Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.